1752 — Nang Kuang Pharmaceutical Co Balance Sheet
0.000.00%
- TWD3.92bn
- TWD4.22bn
- TWD2.20bn
- 94
- 56
- 62
- 85
Annual balance sheet for Nang Kuang Pharmaceutical Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 268 | 418 | 403 | 378 | 303 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 376 | 351 | 387 | 376 | 423 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 1,435 | 1,491 | 1,640 | 1,538 | 1,456 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1,725 | 1,699 | 1,624 | 1,950 | 2,169 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 3,260 | 3,429 | 3,585 | 3,856 | 3,813 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 950 | 1,073 | 1,040 | 1,283 | 1,143 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 1,056 | 1,189 | 1,174 | 1,479 | 1,391 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 2,205 | 2,240 | 2,411 | 2,377 | 2,422 |
| Total Liabilities & Shareholders' Equity | 3,260 | 3,429 | 3,585 | 3,856 | 3,813 |
| Total Common Shares Outstanding |